



10th Annual Update on Liver Disease: A Multidisciplinary Approach

Saturday, March 4, 2023
Clubhouse at Galloping Hill, Kenilworth, NJ

CE Accredited Live Activity Provided by
Rutgers New Jersey Medical School
Department of Medicine
Division of Gastroenterology and Hepatology

Overview

The complexity and magnitude of medical advances in the management of liver disease make it ever more difficult for clinicians to apply this tremendous amount of information to their practice. This activity will provide learners with a comprehensive overview of the state-of-the-art advances in the diagnostic, therapeutic and preventive modalities of liver disease based on the latest evidence, literature and clinical research. A thorough review of the current treatment landscape is vital to both clinicians and patients who can benefit from this expansion of therapeutic options.

Target Audience

This activity is designed for gastroenterologists and hepatologists as well as primary care clinicians including medical internists, family practice physicians, nurses, advanced practice nurses, pharmacists, and physician assistants involved in the diagnosis, management and treatment of patients with liver disease.

Learning Objectives

Upon completion of this activity, participants should be better able to:

- Recognize the risk factors associated with liver disease.
- Review state-of-the-art best practices pertaining to diagnostic and therapeutic strategies in patients with hepatobiliary disease.
- Define the use of therapeutic and preventive modalities including invasive and non-invasive procedures in patients with various liver diseases.
- Discuss the clinical efficacy and safety of therapeutic options for the treatment of liver disease.
- Assess the current literature and emerging clinical research for liver disease management and its impact on clinical practice.

Accreditation



In support of improving patient care, Rutgers Biomedical and Health Sciences is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians: Rutgers Biomedical and Health Sciences designates this live activity for a maximum of 7.25 *AMA PRA Category 1 Credits*[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses: This activity is awarded 7.25 ANCC contact hours.

Pharmacists: This knowledge-based activity qualifies for 7.25 contact hours of continuing pharmacy education credit.

Participants' NABP e-Profile ID and date of birth will be collected during registration. CPE credit will be processed after the program evaluation has closed to participants, which will be three to four weeks following the activity date.

Nurses and pharmacists should claim only those contact hours actually spent participating in the activity.

Physician Assistants: NCCPA accepts certificates of participation for educational activities approved for *AMA PRA Category 1 Credit*[™] from organizations accredited by ACCME.

ABIM MOC Points

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 7.25 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.



Physicians will receive an email no later than Wednesday, March 8, 2023 with instructions for obtaining ABIM MOC points.

Method of Participation

In order to meet the learning objectives and receive continuing education credits, participants are expected to formally register for the activity, check in at the registration desk, attend the activity and complete an online evaluation form at the conclusion of the activity. A CE certificate will be emailed to participants upon completion of the online evaluation.

Agenda

- 7:15 am Registration/Continental Breakfast/Exhibits
- 7:45 am Welcome **Marc Klapholz, MD, MBA**
- 7:50 am Introduction and Presentation of the Carroll M. Leevy, MD
Recognition Award..... **Nikolaos Pyrsopoulos, MD, PhD, MBA**
- Session One Liver Failure - Moderator: Nikolaos Pyrsopoulos, MD, PhD, MBA**
- 8:00 am The Heart (Cirrhotic Cardiomyopathy and EKG Changes) **Marc Klapholz, MD, MBA**
- 8:20 am The Kidney (Hepatorenal - New Definition
and Treatment) **Nikolaos Pyrsopoulos, MD, PhD, MBA**
- 8:40 am The Brain (Hepatic Encephalopathy) **Vivek Lingiah, MD**
- 9:00 am The Lungs (Hepatopulmonary and Hepatic Hydrothorax)..... **Andrew R. Berman MD**
- 9:20 am The Surgeon (Transplant)..... **Grace S. Lee-Riddle, MD, MSME**
- 9:40 am Panel Discussion
- 9:50 am Refreshment Break/Exhibits
- Session Two Viral Hepatitis - Moderator: Mumtaz Niazi, MD**
- 10:00 am Update on Hepatitis C **Alexander T. Lalos, MD**
- 10:30 am Chronic Hepatitis B..... **Ali Wakil, MD**
- 11:00 am Chronic Hepatitis E and Others **Mumtaz Niazi, MD**
- 11:30 am Panel Discussion
- 11:45 am Lunch/Exhibits
- Keynote Presentation**
- 12:15 pm Hepatitis D - An Update in Epidemiology, Screening and Therapy..... **Nancy S. Reau, MD**
- Session Three Tumors and Cholestasis - Moderator: Zaid H. Tafesh, MD, MSc**
- 12:45 pm Medical Approaches for Liver Cancer in 2023 **Ankit Shah, MD/Sharon Li, MD**
- 1:05 pm Primary Biliary Cholangitis **Nikolaos Pyrsopoulos, MD, PhD, MBA**
- 1:30 pm Malignant Biliary Strictures: Can EUS Replace ERCP?..... **Rosario Ligresti, MD**
- 1:50 pm Panel Discussion
- 2:00 pm Refreshment Break/Exhibits
- Session Four NAFLD - Moderator: Sima Vossough-Teehan, MD**
- 2:10 pm Non-Alcoholic Fatty Liver Disease Diagnosis and Treatment in 2023
..... **Zaid H. Tafesh, MD, MSc**
- 2:55 pm Noninvasive Imaging Diagnosis of NAFLD **Humaira S. Chaudhry, MD**
- 3:20 pm Endohepatology and Endosuturing for Obesity/NAFLD **Reza Hashemipour, MD**
- 3:45 pm Panel Discussion
- 4:00 pm Closing Remarks and Adjourn **Nikolaos Pyrsopoulos, MD, PhD, MBA**

Faculty

Activity Director

Nikolaos Pyrsopoulos, MD, PhD, MBA, FACP, AGAF, FAASLD, FRCP (Edin), Professor of Medicine, Chief of Gastroenterology and Hepatology, Professor of Physiology, Pharmacology and Neuroscience, Rutgers New Jersey Medical School; Medical Director, Liver Transplantation, University Hospital, Newark, NJ

Guest Faculty

Nancy S. Reau, MD, Professor and The Richard B. Capps Chair of Hepatology, Division of Digestive Diseases and Nutrition, Department of Internal Medicine, RUSH Medical College; Chief, Section of Hepatology and Associate Director of Organ Transplantation, RUSH University Medical Center, Chicago, IL

Rosario Ligresti, MD, Associate Professor of Medicine, Chief, Division of Gastroenterology, Director, The Pancreas Center, Hackensack University Medical Center, Hackensack, NJ

Sima Vossough-Teehan, MD, Attending Gastroenterologist, East Orange VA Medical Center, East Orange, NJ; Assistant Professor of Medicine, Rutgers New Jersey Medical School, Newark, NJ

Rutgers New Jersey Medical School Faculty

Andrew R. Berman, MD, Professor and Clinical Vice Chair, Director, Division of Pulmonary & Critical Care Medicine and Allergic & Immunologic Diseases, Department of Medicine

Humaira S. Chaudhry, MD, Associate Professor and Interim Chair, Chief, Division of Diagnostic Imaging, Department of Radiology; Chief of Service, University Hospital Radiology

Reza Hashemipour, MD, Advanced Endoscopy Fellow

Marc Klapholz, MD, MBA, FACC, FAHA, Professor and Chair, Department of Medicine; Chief of Service, Department of Medicine, University Hospital

Grace S. Lee-Riddle, MD, MSME, Assistant Professor of Surgery, Division of Transplantation and Hepatobiliary Surgery

Sharon Li, MD, Assistant Professor of Medicine, Division of Hematology and Oncology; Hematologist/Oncologist, Rutgers Cancer Institute of New Jersey

Vivek Lingiah, MD, Transplant Hepatologist

Mumtaz Niazi, MD, Associate Professor of Medicine, Division of Gastroenterology and Hepatology; Director, Outpatient Hepatology Services, University Hospital

Ankit Shah, MD, Assistant Professor of Medicine, Division of Hematology and Oncology; Hematologist/Oncologist, Rutgers Cancer Institute of New Jersey

Zaid H. Tafesh, MD, MSc, Assistant Professor of Medicine, Division of Gastroenterology and Hepatology

Ali Wakil, MD, Assistant Professor of Medicine, Division of Gastroenterology and Hepatology

Rutgers Robert Wood Johnson Medical School Faculty

Alexander T. Lalos, MD, Assistant Professor of Medicine, Division of Gastroenterology and Hepatology

Peer Review

In order to help ensure content objectivity, independence, and fair balance, and to ensure that the content is aligned with the interest of the public, this content has been reviewed by a non-conflicted, qualified reviewer. This activity was peer-reviewed for relevance, accuracy of content, and balance of presentation by:

Merlin Punnoose, PharmD, BCPS, Clinical Pharmacist Specialist, Liver Transplant, University Hospital, Newark, NJ

Kathleen Ruping, BSN, MBA, RN, CCTC, Administrative Director, Center for Advanced Liver Diseases and Transplantation, University Hospital, Newark, NJ

Disclosure Declarations

In accordance with the disclosure policies of RBHS and to conform with Joint Accreditation requirements and FDA guidelines, individuals in a position to control the content of this educational activity are required to disclose to the activity participants: 1) the existence of any relevant financial relationship with any ineligible company, i.e., a company whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients, within the past 24 months; and 2) the identification of a commercial product/device that is unlabeled for use or an investigational use of a product/device not yet approved.

Faculty

The following faculty have no relevant financial relationships with ineligible companies to disclose:

Andrew R. Berman, MD

Humaira S. Chaudhry, MD

Alexander T. Lalos, MD

Grace S. Lee-Riddle, MD, MSME

Sharon Li, MD

Vivek Lingiah, MD

Mumtaz Niazi, MD

Ankit Shah, MD

Zaid H. Tafesh, MD, MSc

Sima Vossough-Teehan, MD

Ali Wakil, MD

The following faculty have relevant financial relationships with ineligible companies:

Reza Hashemipour, MD: Education Course Participant: Boston Scientific

Marc Klapholz, MD: Consultant: Orchestra Biomed, Endotronix; Member, Review Panel: BackBeat Medical, Endotronix

Rosario Ligresti, MD: Consultant: Immunovia, Interpace

Nikolaos Pysopoulos, MD, PhD, MBA: Consultant: Mallinckrodt Pharmaceuticals; Grant/Research Support: CytoSorbents, Durect, Gilead Sciences, Grifols, Intercept Pharmaceuticals, Ocelot Bio, Salix Pharmaceuticals

Nancy S. Reau, MD: Consultant: AbbVie, Arbutus, Gilead Sciences, Intercept Pharmaceuticals, Salix Pharmaceuticals; Grant/Research Support: AbbVie, Eiger BioPharmaceuticals, Gilead Sciences; Member, Review Panel: Arbutus

Planning Committee

The following planners have no relevant financial relationships with ineligible companies to disclose:

Merlin Punnoose, PharmD, BCPS

Kathleen Ruping, BSN, MBA, RN, CCTC

RBHS Center for Continuing and Outreach Education Staff

Patrick Dwyer, Director, Continuing Medical Education, and Olinda Perez, Program Coordinator, have no relevant financial relationships with ineligible companies to disclose.

Off-Label/Investigational Use

Speakers are required to disclose discussion of off-label/investigational uses of commercial products/devices in their presentation. These disclosures will be made to the audience at the time of the activity.

Audience Handouts

There will be no handouts provided at the activity. Speaker slide presentations are available online at:

<https://sites.rutgers.edu/ccoe/23MN07/>

Unless otherwise noted, the handouts are provided in .pdf format and must be read using Adobe Acrobat Reader. If you do not have Adobe Acrobat Reader, download a free copy of this software at

Computers <http://get.adobe.com/reader/>

Mobile Devices <http://www.adobe.com/products/reader-mobile.html>



WiFi

Network: Galloping Hill Guest / no password needed

or

Network: Galloping Hill Events / Password: Events2021

Evaluation and CE/Attendance Certificates

Following the program, we ask that you take a few moments to complete the online evaluation survey to assist us in assessing the effectiveness of this activity and to make recommendations for future educational offerings. Your response will help ensure that future programs are informative and meet the educational needs of all participants.

In order to obtain a CE/attendance certificate, you must complete the online evaluation. The evaluation and certificates are ONLY available online.

An email will be sent to you no later than Wednesday, March 8, 2023 with instructions for accessing the evaluation and obtaining your CE/attendance certificate.

ABIM MOC Points

ABIM Board Certified Physicians seeking ABIM MOC Points are also required to complete an online post-test consisting of a series of multiple-choice questions and achieve a minimum passing score. Upon successfully completing the post-test in addition to completing the online evaluation described above, RBHS will report your participation and MOC points to ABIM through ACCME, the CME accrediting body, approximately 4 weeks after the activity. You will be notified when this is complete.

An email will be sent to physicians no later than Wednesday, March 8, 2023 with instructions for accessing the post test.

Disclaimer

The views expressed in this activity are those of the faculty. It should not be inferred or assumed that they are expressing the views of any manufacturer of pharmaceuticals or devices or, RBHS.

It should be noted that the recommendations made herein with regard to the use of therapeutic agents, varying disease states, and assessments of risk, are based upon a combination of clinical trials, current guidelines, and the clinical practice experience of the participating presenters. The drug selection and dosage information presented in this activity are believed to be accurate. However, participants are urged to consult all available data on products or procedures before using them in clinical practice.

RBHS reserves the right to modify the activity content and faculty if necessary.

Copyright © 2023. Rutgers Biomedical and Health Sciences. All rights reserved including translation into other languages. No part of this activity may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, or any information storage and retrieval systems, without permission in writing from Rutgers.

For questions or concerns regarding this activity, please contact CCOE at ccoe@rbhs.rutgers.edu



New Jersey Medical School

10th Annual Update on Liver Disease

Supporters

This activity is supported in part by educational grants from:

Gilead Sciences, Inc.

Intercept Pharmaceuticals, Inc.

Mallinckrodt Pharmaceuticals

Grifols USA

Salix Pharmaceuticals, Inc.

Takeda Pharmaceuticals USA, Inc.

Exhibitors

We wish to thank our exhibitors for their participation.

Please visit our exhibit hall to find relevant educational materials.

AbbVie Inc.

Genentech USA, Inc.

Gilead Sciences, Inc.

Intercept Pharmaceuticals, Inc.

Mallinckrodt Pharmaceuticals

Salix Pharmaceuticals, Inc.

Takeda Pharmaceuticals USA, Inc.